Sacituzumab Govitecan-hziy in Pre-Treated HR+/HER2– Advanced Breast Cancer

home / approval-alert / sacituzumab-govitecan-hziy-in-pre-treated-hr-her2-advanced-breast-cancer

Sacituzumab Govitecan-hziy in Pre-Treated HR+/HER2– Advanced Breast Cancer

Articles
Patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer can now receive treatment with sacituzumab govitecan following approval from the FDA.

FDA Approves Sacituzumab Govitecan-hziy in Pre-Treated HR+/HER2– Advanced Breast Cancer

February 3rd 2023

Patients with pre-treated, unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer can now receive treatment with sacituzumab govitecan following approval from the FDA.

Podcasts
Experts from Emory Winship Cancer Institute discuss how the FDA approval of sacituzumab govitecan will impact the treatment of breast cancer.

Oncology On-the-Go Podcast: Sacituzumab Govitecan for HR+/HER2– Advanced Breast Cancer

February 20th 2023

Experts from Emory Winship Cancer Institute discuss how the FDA approval of sacituzumab govitecan will impact the treatment of breast cancer.

Videos
An expert from Dana-Farber Cancer Institute discusses what the approval of sacituzumab govitecan means for patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Sacituzumab Govitecan Approval Gives ‘Meaningful’ Survival in Advanced HR+ Breast Cancer

February 3rd 2023

An expert from Dana-Farber Cancer Institute discusses what the approval of sacituzumab govitecan means for patients with advanced hormone receptor–positive, HER2-negative breast cancer.